Dendreon Corporation Shares Halted Ahead of FDA Meeting

March 29, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

SAN FRANCISCO (MarketWatch) -- Shares of Dendreon Corp. were halted before the start of trading Thursday, ahead of a Food and Drug Administration advisory committee meeting to evaluate Provenge, the company's experimental prostate-cancer drug.

>>> Discuss This Story

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

Food and Drug Administration (FDA)